The Malaria Vaccine Implementation Program (MVIP) Evaluation in Kenya is a collaboration between the Kenya Medical Research Institute (KEMRI) and the Centers for Disease Control and Prevention, USA (CDC).
The vaccine will be implemented by the National Vaccines and Immunizations Program (NVIP) in moderate to high malaria transmission settings in eight counties in Western Kenya: Bungoma, Busia, Homa Bay, Kakamega, Kisumu, Migori, Siaya,
and Vihiga.
The primary objective of this evaluation is to estimate the effect of the routine delivery of RTS,S/AS01 on all-cause mortality in children aged 5-48 months.
Secondary study objectives include evaluation of the safety and feasibility of vaccine implementation in this setting. The Malaria Branch has a vacancy for Field/Community Interviewer in the Malaria Vaccine Pilot Evaluation study;
